<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83906">
  <stage>Registered</stage>
  <submitdate>8/05/2009</submitdate>
  <approvaldate>5/06/2009</approvaldate>
  <actrnumber>ACTRN12609000417280</actrnumber>
  <trial_identification>
    <studytitle>Analysis of the immunomodulatory effects of Echinacea</studytitle>
    <scientifictitle>investigations into the effects of supplementation with echinacea on parameters of the immune response in healthy adults</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Immune system response</healthcondition>
    <conditioncode>
      <conditioncode1>Alternative and complementary medicine</conditioncode1>
      <conditioncode2>Herbal remedies</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Normal development and function of the immune system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The tablets contain 675mg herb equivalent of Echinacea purpurea and 600mg herb equivalent of Echinacea angustifolia.  Participants will take 2 tablets twice a day for 2 weeks</interventions>
    <comparator>Each participant is their own control as they are tested before and after echinacea supplementation</comparator>
    <control>Active</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Blood analysis of white blood cell types, heat chock protein expression levels and alkylamide concentrations will be assessed</outcome>
      <timepoint>Baseline and on completion of the 2 week supplementation period</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Single dose pharmacokinetics will be examined in blood before and after the supplementation period.</outcome>
      <timepoint>Before and after the 2 weeks supplementation period</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy individuals exhibiting no sign of respiratory illness in the 2 weeks before the trial commences.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Plant/pollen allery
Lactation or pregnancy
Diagnosed respiratory disease</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Pharmacokinetics</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2 / Phase 3</phase>
    <anticipatedstartdate>20/05/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>MediHerb Pty Ltd</primarysponsorname>
    <primarysponsoraddress>3/85 Brandl St
Eight Mile Plains
QLD 4113</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>MediHerb Pty Ltd</fundingname>
      <fundingaddress>3/85 Brandl St
Eight Mile Plains
QLD 4113</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>AusIndustry - Commercial Ready Grant</fundingname>
      <fundingaddress>Department of Innovation, Industry, Science and Research
Level 12, 100 Creek St, Brisbane, QLD 4000</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>It is widely accepted that stimulation of the immune system is responsible for the perceived benefits of Echinacea.  This study will examine the prophylactic use of echinacea on white cell counts, natural killer cell functionality, heat shock protein expression and echinacea pharmacokinetics.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Human Research Ethics Committee</ethicname>
      <ethicaddress>University of New England
Research Development and Integrity Research Services
Armidale, NSW 2351</ethicaddress>
      <ethicapprovaldate>6/03/2009</ethicapprovaldate>
      <hrec>HE09/017</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Linda Agnew</name>
      <address>Centre for Bioactive Discovery in Health and Ageing
School of Science and Technology
McClymont Building
University of New England
Armidale NSW 2351</address>
      <phone>+61 2 6773 2631</phone>
      <fax />
      <email>lagnew2@une.com.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Linda Agnew</name>
      <address>Centre for Bioactive Discovery in Health and Ageing
School of Science and Technology
McClymont Building
University of New England
Armidale NSW 2351</address>
      <phone>+61 2 6773 2631</phone>
      <fax />
      <email>lagnew2@une.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Anita Matthias</name>
      <address>3/85 Brandl St
Eight Mile Plains
QLD 4113</address>
      <phone>+61 7 3423 6524</phone>
      <fax />
      <email>anita.matthias@mediherb.com.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>